Revolutionizing Regenerative Medicine: Restoring Health and Function with Cutting-Edge Stem Cell Therapy

Our Discovery of Potent Angiogenic
and Regenerative Effects of Cultured ADRCs

We are dedicated to addressing the unmet clinical need for stem cell treatment of chronic diseases. Our research focuses on understanding the properties and origin of stem cell populations, including Adipose Derived Regenerative Cells (ADRCs), which are known to be heterogenous. Our goal is to gain a better understanding of how stem cell treatments can modify or even cure diseases.

Our team has made an exciting discovery – specifically cultured ADRCs have potent angiogenic and regenerative effects.  In phase 1 trials, we have found that a single injection of the patient’s own ADRCs has reversed erectile dysfunction in prostatectomized men.We are committed to advancing our understanding of stem cells and to bringing safe and effective treatments to patients in need.

At Blue Cell Therapeutics, we believe in the power of collaboration and are proud to work with leading researchers, clinicians, and institutions worldwide to advance the field of regenerative medicine. Our state-of-the-art facilities and dedicated team of experts ensure that our treatments are of the highest quality and safety. We are passionate about improving patients’ lives, and our commitment to ethical and responsible research and treatment is at the forefront of everything we do.


Revolutionizing Chronic Disease Treatment with Blue Cell Therapy: We’re committed to bringing the regenerative power of Blue Cells to patients with chronic diseases, starting with erectile dysfunction. We are developing ‘over the counter’ allogenic treatments to increase efficiency and availability while reducing costs. Our cutting-edge research translates basic science into life-changing treatments.


At our Blue Cell Therapeutics, our mission is to provide safe and effective treatment for Erectile Dysfunction by introducing Blue Cell therapy as the gold standard in hospitals and clinics worldwide. To achieve this, we have established a multi-step plan to develop Blue Cell products and methodologies that are both efficient and cost-effective.

As a first step we have developed new methods for Blue Cell isolation primary to optimize autologous stem cell treatment. We have, increased efficiency and reducing treatment costs by a factor of 2-3.

Secondly, to move into allogeneic treatment, we have developed a GMP compliant cell culture of the blue cells isolated adipose tissue. We are now establishing the reproducibility, safety, efficacy, and adverse effects of autologous Blue Cells for the treatment of Erectile Dysfunction and other diseases.

Our goal is to make this life-changing treatment available to patients worldwide and to improve their quality of life.

"The safety of using the patients
own Blue Cells will increase
acceptance for large scale uptake."


Discovering the Power of Blue Cells:
Our Journey to Revolutionize Stem Cell Therapy for Erectile Dysfunction and Beyond

Five years ago, Søren P Sheikh (SPS) embarked on a mission to bring a new stem/progenitor cell treatment to patients. To achieve this goal, SPS took a leave of absence and traveled the world for three months, visiting multiple laboratories. After careful consideration, ADRCs were chosen as the cells to use for therapy, as there were approved systems for their isolation, and they could potentially be more easily approved by regulatory bodies since they come from the patient’s own body. The disease Erectile Dysfunction was selected because of promising preclinical data showing ADRCs could correct ED in rat models, but this had not yet been tested in humans.
In 2016, the Danish Medicines Agency approved a phase 1 trial using ADRCs to treat ED after prostate cancer surgery at Odense University Hospital in Denmark. 

These men had no erectile function and did not respond to drugs like Viagra. The results were promising, with 72% of the men regaining erectile function and the ability to engage in sexual intercourse.

During the trial, researchers kept 20% of each ADRC mixture for laboratory analysis and identified a single cell type, called Blue Cells, among the 12-14 different cell types in the ADRC mixture, that correlated with the regenerative effect on ED. Further in vitro assays, single-cell RNA sequencing, and proteomics confirmed the strong angiogenic and regenerative potential of the cells.

Blue Cell Therapeutics aims to use Blue Cells as a platform for autologous and allogenic treatment for several diseases, including erectile dysfunction.

Blue Cells

Use of ADRCs can yield inconsistent results due to the heterogeneous nature of the acquired cells and different methods of isolation and preparation. For large scale clinical uptake…


Blue Cell Therapeutics has been granted a license to the patent rights that protect the technology we work with. This license was provided by the University of Southern Denmark and Odense University Hospital. In addition, we have received funding from the Danish Innovation Fund and the Eurostars program, with Novozymes serving as a partner in both projects.